Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  The American Economic Review

• Publication date

  2015-07-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1257/AER.20131176PMID 29543421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risks to the Returns to Medical Innovation: The Case of Myriad Genetics

  2017cited by this paper
• Why Is Research in Early-Stage Cancer Research so Low? A Re-Assessment of Budish, Roin and Williams (2015)

  2017cited by this paper
• The American College of Preventive Medicine Policy Recommendations on Public Health Funding.

  2017cited by this paper
• Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes

  2017cited by this paper
• Killer Acquisitions ∗

  2017cited by this paper
• An FDA Commissioner for the 21st Century.

  2017cited by this paper
• Developing Novel Drugs

  2017cited by this paper
• Innovation: The interplay between demand-side shock and supply-side environment

  2017cited by this paper
• CEO Contract Horizon and Innovation

  2017cited by this paper
• Lending to Innovative Firms

  2017cited by this paper
• Participation inertia in R&D tax incentive and subsidy programs

  2017cited by this paper
• The direction of innovation

  2017cited by this paper
• CNS Anticancer Drug Discovery and Development: 2016 conference insights.

  2017cited by this paper
• Tort Reform and Innovation

  2017cited by this paper
• How do patents affect research investments?

  2017cited by this paper
• Appendix for : Patents and Research Investments : Assessing the Empirical Evidence

  2016influential reference
• A Theory of Efficient Short-Termism

  2016cited by this paper
• Improving Investor-Investee Matches with Regulation: Evidence from the Orphan Drug Act & Global Biotechnology Industry

  2016cited by this paper
• The Unaccounted Insurance Value of Medical Innovation

  2016cited by this paper
• Technology and Time Inconsistency∗

  2016cited by this paper
• Patents as a Spur to Subsequent Innovation: Evidence from Pharmaceuticals

  2016cited by this paper
• Personalized medicine in neuro-oncology.

  2016influential reference
• Disease Interception: Myths, Mountains, and Mole Hills

  2016cited by this paper
• On the Road to Innovation: The Role of Venture Capital

  2015cited by this paper
• Do firms underinvest in long-term research? Evidence from cancer clinical trials.

  2015cited by this paper
• Patent Duration, Breadth and Costly Imitation: Evidence from the U.S. Pharmaceutical Market

  2015cited by this paper
• Does Going Public Affect Innovation

  2015cited by this paper
• Market Size and Pharmaceutical Innovation

  2015cited by this paper
• Patent rights, product market reforms, and innovation

  2015cited by this paper
• Patent Rights, Innovation and Firm Exit

  2015cited by this paper
• NBER WORKING PAPER SERIES THE CAUSAL EFFECTS OF COMPETITION ON INNOVATION: EXPERIMENTAL EVIDENCE

  2014cited by this paper
• Innovation under Regulatory Uncertainty: Evidence from Medical Technology.

  2014cited by this paper
• Entry and Investment Decisions in the Pharmaceutical Industry

  2014cited by this paper
• The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.

  2014cited by this paper
• Corporate Investment and Stock Market Listing

  2014cited by this paper
• Do Pharmacists Buy Bayer? Sophisticated Shoppers and the Brand Premium

  2013cited by this paper
• The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files

  2013cited by this paper
• Handbook of the Economics of Finance

  2013cited by this paper
• Regulatory innovation and drug development for early-stage Alzheimer's disease.

  2013cited by this paper
• Market Power Screens Willingness-to-Pay

  2012cited by this paper
• Cost–effectiveness of statins revisited: lessons learned about the value of innovation

  2012cited by this paper
• Evergreening, patent challenges, and effective market life in pharmaceuticals.

  2012cited by this paper
• The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research.

  2012cited by this paper
• Reinventing clinical trials

  2012cited by this paper
• Pass-Through and Demand Forms∗

  2012cited by this paper
• The Segmentation of Therapeutic Populations in Oncology

  2012cited by this paper
• Radiotherapy and short-term androgen deprivation for localized prostate cancer.

  2011cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• NBER WORKING PAPER SERIES CAN MEDICAL PROGRESS BE SUSTAINED? IMPLICATIONS OF THE LINK BETWEEN DEVELOPMENT AND OUTPUT MARKETS

  2011cited by this paper
• Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic

  2011influential reference
• Mostly Harmless Econometrics: An Empiricist's Companion

  2011cited by this paper
• Terminal Care and the Value of Life Near its End

  2010cited by this paper
• Valuing fatal risks to children and adults: Effects of disease, latency, and risk aversion

  2010cited by this paper
• The Emperor of All Maladies: A Biography of Cancer

  2010cited by this paper
• Introduction to Clinical Trials

  2010cited by this paper
• The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development

  2009cited by this paper
• Launching a Thousand Ships : Incentives for Parallel Innovation

  2009cited by this paper
• Cancer prevention: from 1727 to milestones of the past 100 years.

  2009cited by this paper
• Discover a Drug Substance, Formulate, and Develop It to a Product

  2008cited by this paper
• Off-label use of anticancer drugs.

  2008cited by this paper
• Mostly Harmless Econometrics: An Empiricist's Companion

  2008cited by this paper
• Improving the Quality of Cancer Clinical Trials: Workshop Summary

  2008cited by this paper
• Generic competition and market exclusivity periods in pharmaceuticals

  2007cited by this paper
• Advances in the prevention and treatment of cardiovascular disease.

  2007cited by this paper
• Treatment options for actinic keratoses.

  2007cited by this paper
• The Danger of Underdeveloped Patent Prospects

  2007cited by this paper
• The Value of Health and Longevity

  2006cited by this paper
• Developing drugs for developing countries.

  2006cited by this paper
• Estimating the cost of new drug development: is it really 802 million dollars?

  2006cited by this paper
• Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs

  2006cited by this paper
• Drug Discovery: From Bedside to Wall Street

  2005cited by this paper
• Surrogate endpoints and FDA's accelerated approval process.

  2005cited by this paper
• Identifying Technology Spillovers and Product Market Rivalry

  2005cited by this paper
• Decision Points in Drug Development

  2005cited by this paper
• How Do Patent Laws Influence Innovation? Evidence from Nineteenth-Century World Fairs

  2005cited by this paper
• The problem of new uses.

  2005cited by this paper
• Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry

  2004cited by this paper
• Your Money or Your Life: Strong Medicine for America's Health Care System

  2004influential reference
• Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry

  2004cited by this paper
• Schumpeterian Profits in the American Economy: Theory and Measurement

  2004cited by this paper
• The price of innovation: new estimates of drug development costs.

  2003cited by this paper
• Fundamentals of Medicinal Chemistry

  2003cited by this paper
• The Return to Biomedical Research: Treatment and Behavioral Effects

  2003cited by this paper
• Modelling Survival Data in Medical Research, Second Edition

  2003cited by this paper
• End points and United States Food and Drug Administration approval of oncology drugs.

  2003cited by this paper
• NBER WORKING PAPER SERIES ESTIMATES OF THE VALUE OF PATENT RIGHTS IN EUROPEAN COUNTRIES DURING THE POST-1950 PERIOD

  2002cited by this paper
• Patent Protection and Innovation Over 150 Years

  2002cited by this paper
• Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patent Law Reforms

  2001cited by this paper
• Medicinal Chemistry: An Introduction

  2000cited by this paper
• Are increasing 5-year survival rates evidence of success against cancer?

  2000cited by this paper
• Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not)

  2000cited by this paper
• Response rates, survival, and chemotherapy trials.

  2000cited by this paper
• Overview of the Hatch-Waxman Act and its impact on the drug development process.

  1999cited by this paper
• Tamoxifen prevention of breast cancer: an instance of the fingerpost.

  1999cited by this paper
• Staged Financing: An Agency Perspective

  1999cited by this paper
• Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.

  1999cited by this paper
• Overview of the Hatch-Waxman Act and its impact on the drug development process.

  1999cited by this paper
• Why the Far-Distant Future Should Be Discounted at Its Lowest Possible Rate

  1998cited by this paper
• Patent Buyouts: A Mechanism for Encouraging Innovation

  1998cited by this paper
• International protection of intellectual property

  1996cited by this paper

• The Demographic and GDP Impacts of Slowing Biological Aging

  2026cites this paper
• Macroprudential policy and corporate long-term investment: evidence from China

  2026cites this paper
• Legalization and innovation in the cannabis market

  2026cites this paper
• Regulatory delays and patent term erosion in medical device innovation: a two-market analysis of EU and US frameworks

  2026cites this paper
• Race to the Bottom: Competition and Quality in Science

  2025cites this paper
• The Changing Nature of Firm Innovation: Short-Termism and Influential Innovation in U.S. Public Firms

  2025cites this paper
• Surrogate end points in oncology: aligning drug development incentives and patient needs

  2025cites this paper
• The persistent receipt of R&D subsidies and the promotion of SME innovation: evidence from China

  2025cites this paper
• Policies to Reduce Federal Budget Deficits by Increasing Economic Growth

  2025cites this paper
• Information Disclosure and Peer Innovation: Evidence from Mandatory Reporting of Clinical Trials

  2025cites this paper
• Estimating the Economic and Budgetary Effects of Research Investments

  2025cites this paper
• Indirect Cost Recovery in U.S. Innovation Policy: History, Evidence, and Avenues for Reform

  2025cites this paper
• Marketing authorization and strategic patenting: Evidence from pharmaceuticals

  2025cites this paper
• An analysis of US net cancer drug launch prices and clinical efficacy and certainty of evidence from 2008 to 2022

  2025cites this paper
• Nonparametric Jackknife Instrumental Variable Estimation and Confounding Robust Surrogate Indices

  2024cites this paper
• Lifestyle choices among women with breast cancer in the United States

  2024cites this paper
• Government Intervention in Innovation

  2024cites this paper
• Dynamic Scoring: A Progress Report on Why, When, and How

  2024cites this paper
• Information Disclosure and Competitive Dynamics: Evidence from the Pharmaceutical Industry

  2024cites this paper
• An FDA for AI? Pitfalls and Plausibility of Approval Regulation for Frontier Artificial Intelligence

  2024cites this paper
• Pull me – push you? The disparate financing mechanisms of drug research in global health

  2024cites this paper
• Funding of Clinical Trials and Reported Drug Efficacy

  2024cites this paper
• Pricing Innovation in Surgical Care Markets

  2024cites this paper
• How firm’s perception of economic policy uncertainty influences innovation quality

  2024cites this paper
• Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D.

  2024cites this paper
• Gains from Patent Protection: Innovation, Market Power and Cost Savings in India

  2024cites this paper
• Patent term extensions and commercialization lags in the pharmaceutical industry: A growth-theoretic analysis

  2023influential citation
• Competition for Exclusivity and Customer Lock-in: Evidence from Copyright Enforcement in China

  2023cites this paper
• Does firm financialization affect optimal real investment decisions? Evidence from China

  2023cites this paper
• Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model

  2023cites this paper
• Market Exclusivity and Innovation: Evidence From Antibiotics

  2023cites this paper
• Distorted Innovation: Does the Market Get the Direction of Technology Right?

  2023influential citation
• Association of Hospital Adoption of Probiotics With Outcomes Among Neonates With Very Low Birth Weight

  2023cites this paper
• Improving Regulation for Innovation: Evidence from China's Pharmaceutical Industry

  2023cites this paper
• An Optional Delinked Reward System: Making Pharmaceutical Innovation Work for Everyone

  2023cites this paper
• Short-term incentives of research evaluations: Evidence from the UK Research Excellence Framework

  2023cites this paper
• The Political Economy of a “Miracle Cure”: The Case of Nebulized Ibuprofen and its Diffusion in Argentina

  2023cites this paper
• If You Build It, They Will Come: The Impact of Clinical Trial Experience on African Science

  2023cites this paper
• The Generic Drug Trilemma

  2023cites this paper
• Promoting Innovation: The Differential Impact of R&D Subsidies

  2023cites this paper
• Innovation Market Failures and the Design of New Climate Policy Instruments

  2023cites this paper
• Intellectual Property Protection Lost and Competition: An Examination Using Large Language Models

  2023cites this paper
• Excess Commitment in R&D

  2023cites this paper
• The Incentive and Welfare Effects of the European Unitary Patent∗

  2023cites this paper
• Patent power in biomedical innovation: Technology governance in biomodifying technologies

  2022cites this paper
• Excess of everything is bad: CEO greed and corporate policies

  2022cites this paper
• Intellectual Property Protection Lost and Competition: An Examination Using Machine Learning

  2022influential citation
• Causal Inference During a Pandemic: Evidence on the Effectiveness of Nebulized Ibuprofen as an Unproven Treatment for COVID-19 in Argentina

  2022cites this paper
• Generic competition and the incentives for early-stage pharmaceutical innovation

  2022cites this paper
• Intellectual Property Protection Lost: The Impact on Competition and Acquisitions

  2022cites this paper
• Incentives for Pharmaceutical Innovation: What’s Working, What’s Lacking

  2022cites this paper
• R&D Competition and the Direction of Innovation

  2022cites this paper
• Patent System in the Digital Era - Opportunities and New Challenges

  2022cites this paper
• Networks and Economic Fragility

  2022cites this paper
• The Macro Impact of Short-Termism∗

  2022cites this paper
• Learning by Selling, Knowledge Spillovers, and Patents*

  2022cites this paper
• REPRESENTATION AND EXTRAPOLATION: EVIDENCE FROM CLINICAL TRIALS.

  2022cites this paper
• The Real Effects of Equity Markets on Innovation

  2022cites this paper
• Financing Biomedical Innovation

  2022cites this paper
• Are Transformational Ideas Harder to Fund? Resource Allocation to R&D Projects at a Global Pharmaceutical Firm

  2022cites this paper
• Financial Intermediation and the Funding of Biomedical Innovation: A Review

  2022cites this paper
• Too Costly to Convince: how do startups deliver radical innovation via partnership?

  2022cites this paper
• Of Academics and Creative Destruction: Startup Advantage in the Process of Innovation

  2022cites this paper
• Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

  2022cites this paper
• Regulating the Innovators: Approval Costs and Innovation in Medical Technologies

  2022influential citation
• What drives innovation? Lessons from COVID-19 R&D

  2021cites this paper
• Uncertainty and Risk-Taking in Science: Meaning, Measurement and Management

  2021cites this paper
• Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis

  2021cites this paper
• Still in Mortal Peril? Recent Research Suggests a New Agenda for Health Care Reform

  2021cites this paper
• R&D and market size: Who benefits from orphan drug legislation?

  2021cites this paper
• Effect of changing business R&D expenditure mix on productivity of the South African national system of innovation

  2021cites this paper
• Regulatory Approval and Expanded Market Size

  2021cites this paper
• The Organization of Innovation: Property Rights and the Outsourcing Decision

  2021cites this paper
• How does firm innovation size affect the timing of technology licensing? Theory and evidence from China

  2021cites this paper
• Competition and Innovation Revisited: A Product-Level View

  2021cites this paper
• Resource Allocation Among Competing Innovators

  2021cites this paper
• Pharmainnovationen: überragende Position der USA und Schwächen der deutschen Forschung

  2021cites this paper
• The Past and Future of Economic Growth: A Semi-Endogenous Perspective

  2021cites this paper
• Financialization of manufacturing companies and corporate innovation: Lessons from an emerging economy

  2021cites this paper
• Trials and Terminations: Learning from Competitors' R&D Failures

  2021cites this paper
• On the Direction of Innovation

  2021cites this paper
• Do government-funded patents have higher quality than privately-funded patents?

  2021cites this paper
• Augmenting State Capacity for Child Development: Experimental Evidence from India

  2021cites this paper
• Flowers of Invention: Patent Protection and Productivity Growth in US Agriculture

  2021influential citation
• How research evaluations can damage scientific quality: 23 years of evidence from the UK Research Excellence Framework

  2021cites this paper
• RENISUS Plants and Their Potential Antitumor Effects in Clinical Trials and Registered Patents

  2020cites this paper
• Direction of Innovation During a Crisis

  2020cites this paper
• Abnormal Returns and Dispersion in Cybersecurity Exposure

  2020cites this paper
• Subsidy Spillovers , Two Ways ∗

  2020cites this paper
• Generating comparative evidence on new drugs and devices after approval.

  2020cites this paper
• Enhanced Information Disclosure and Drug Development: Evidence from Mandatory Reporting of Clinical Trials

  2020cites this paper
• Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents

  2020cites this paper
• Generating comparative evidence on new drugs and devices before approval.

  2020cites this paper
• The green economy transition: the challenges of technological change for sustainability

  2020cites this paper
• Innovation During a Crisis: Evidence from Covid-19

  2020cites this paper
• Crises and the Direction of Innovation

  2020cites this paper
• New Medicines for Serious Diseases: The Case of the FDA’s Breakthrough Designation

  2020cites this paper
• The Challenges of Measuring Scientific Research Productivity and Impact in Developing Economies

  2020cites this paper
• The Promise of a Cure: Measuring the Welfare Gain to Hemophilia a Patients From Gene Therapy

  2020cites this paper
• Recalls and Innovation: Own and Competitor Firm Response

  2020cites this paper